Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Connetics Corporation has announced that results of a phase IV clinical study evaluating the long-term efficacy of a lower dosage of Soriatane show that low-dose regimens of the drug over a six-month period are effective and well tolerated in the treatment of adults with moderate-to-severe plaque-type psoriasis.
Subscribe to our email newsletter
The study was a phase IV, multicenter, open-label, randomized study evaluating the long-term efficacy of a lower dosage of Soriatane in 77 psoriasis patients. Patients were randomized to receive either 25mg of Soriatane once daily with food for 24 weeks, or 25mg of Soriatane once daily with food for 12 weeks followed by a ‘step down’ dosing regimen of 10mg once daily for 12 weeks.
“The current Soriatane treatment practice is to administer the maximum tolerable dose, ranging from 25mg to 50mg per day, while managing the dose-related side effect profile,” said Dr Jennifer Cather from Modern Dermatology, Baylor University Medical Center in Dallas, Texas. “This has been the treatment protocol believed to achieve the greatest patient efficacy benefit. These study results are significant, because they demonstrate that administering Soriatane at the minimal and therefore more tolerable, daily dosing regimen of 10 or 25mg over a six-month period is as effective when compared to the more aggressive treatment regimen in practice today.”